It has been reported that a significant reduction in the accumulation of polymorphonuclear leucocytes (PMNs) in skin chambers occurs in patients with rheumatoid arthritis (RA) compared with controls who were either normal subjects or patients with osteoarthrosis.1 The depressed cellular response could be due to one or more of a variety of factors, but most attention has been given to possible alterations in PMN migration. It has been reported that both cellular and humoral defects are present in the circulation of patients with RA. '2 In this communication we present evidence that a heat-labile factor which inhibits the movement of both PMNs and peripheral mononuclear phagocytes (MN) in vitro is present in the plasma of patients with RA.
Patients and methods
All the patients reported on in this study were attending rheum4tology outpatient clinics at King's College Hospital and had either definite or classical rheumatoid arthritis (RA group) or were suffering from either osteoarthrosis or low back pain (control group). All the RA group and a number of the control patients were being treated with nonsteroidal anti-inflammatory drugs, In addition, penicillamine, and occasionally gold and steroids, were being administered to the patients with RA.
Accepted for publication 13 December 1979 Correspondence to Dr J. R. Walker MN) were placed in the centre well and 2 ,.1 of control or RA plasma was added to the cells. FMLP (10-6 M) and undiluted zymosan-activated plasma were used as attractants for the PMNs and MNs respectively. After 2 h (PMN) or 22 h (MN) incubation in a humid atmosphere at 370C the plates were fixed with methanol, assessed as described previously, and the results expressed as the chemotactic differential, that is, the distance moved by directed migration.
Boyden chambers. The response of unwashed PMNs prepared from blood samples from the patients with RA and the control group, towards zymosan-activated plasma from subjects in the control group was studied in modified Boyden chambers (Neuroprobe Inc., Maryland, USA). The cells were prepared as described above and suspended in MEM to a standard concentration of 2 5 x 106/ml and placed in the upper compartment of chambers fitted with 5 ,um Millipore filters. The activated plasma diluted (5% v/v) in MEM was placed in the lower chamber. After 90 min incubation at 370C in a humid atmosphere the filters were removed, stained, and the numbers of cells reaching the lower surface of the filters per high-power field (x 400) were counted as described previously.'
Results
The effects of the plasmas on aspects of leucocyte movement in vitro are shown in Tables 1-3 . A consistent finding was that only untreated plasma from patients with RA significantly inhibited the random migration of both PMNs and MNs (Table  1) , the chemokinetic response of PMNs to FMLP (Table 2) , and the directed migration of PMNs to FMLP and MNs to zymosan-activated plasma (Table 3) . A heat-labile factor which interfered with the locomotion of both PMNs and MNs in vitro was therefore present in the circulation of patients with RA. The results given in Table 4 show that unwashed preparations of leucocytes, prepared from blood samples from patients with RA responded to a significantly lesser degree to zymosan-activated plasma than corresponding preparations of leucocytes from control patients. The period of the experiment (90 min) was such that only PMN movement was measured.
Discussion
The results of the present work show the presence of a factor in the plasma of patients with RA which inhibits the random movement and stimulated migration, both random and directed, of normal PMNs and MNs in vitro. This factor is heat-labile, being destroyed by heating at 560C for 30 min, exerts a direct action on the cells, and is absent from the plasma of patients with either osteoarthrosis or back pain, that is, suffering from noninflammatory conditions. The presence of this material in the circulation of patients with RA could explain the reduced accumulation of PMNs found to occur in skin chambers in such patients.' As in our previous study, there was no apparent relationship between the inhibitory activity observed in any one patient's or group of patients' plasmas and drug therapy.
Its relation to other reported defects of leucocyte movement in patients with RA is of interest. Mowat and Baum,2 using a filter assay, found that PMNs from the blood of patients with RA were significantly less responsive to chemotaxins than were the corresponding cells from normal subjects. This effect was not observed by Walker et al., ' 7 but the experimental conditions used by both groups of workers differed with respect to the extent of washing of the isolated leucocyte preparations. It has recently been demonstrated8 that when PMN preparations are washed with saline or buffers there is a progressive removal of proteins, including activators of cell migration. In the present work the minimum of washing during the preparation procedures produced a leucocyte preparation from the blood of patients with RA which was significantly less responsive to chemotactic stimuli than leucocytes from control patients (Table 4) . It is therefore suggested that the heat-labile inhibitor of leucocyte movement found in the plasma of patients with RA is weakly bound to leucocytes in the circulation. Its presence would explain the experimental findings of Mowat and Baum,2 who did not wash their leucocyte preparations and its removal in vitro would explain the results of Walker et al.,7 who washed their leucocyte suspensions several times before use.
An inhibitory material described by Walker et aL.l differs from the present factor in being heat-stable and not formed in the plasma from patients with RA until the plasma has been activated by zymosan. The heat-stable inhibitor also affects the migration of MNs and occurs in some of the RA patients in which the heat-labile factor is absent (unpublished data). The 2 factqrs cannot be identical, but they may both be produced during the development of chronic inflammatory diseases such as RA. 
